NASDAQ:ADRX ADARx Pharmaceuticals 11/12/2026 Earnings Results & Report $14.91 +1.61 (+12.11%) As of 04:00 PM Eastern ADARx Pharmaceuticals missed analyst earnings expectations in results released November 12, 2026. The company reported EPS of -$1.74 versus the -$0.40 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details Report DateNovember 12, 2026TimeAfter Market Closes ADARx Pharmaceuticals EPS ResultsActual EPS-$1.74Consensus EPS -$0.40Beat/MissMissed by -$1.34One Year Ago EPSN/AADARx Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile ADARx Pharmaceuticals Earnings FAQ Did ADARx Pharmaceuticals beat earnings estimates for the quarter? ADARx Pharmaceuticals (NASDAQ:ADRX) reported earnings of -$1.74 per share for the quarter, missing the consensus estimate of -$0.40. The report was announced on Thursday, November 12, 2026. ADARx Pharmaceuticals Earnings HeadlinesEarnings Flash (ADRX) ADARx Pharmaceuticals, Inc. Reports Q3 Revenue $2.2M, vs. FactSet Est of $2.6M17 minutes ago | marketscreener.comMADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates1 hour ago | globenewswire.comA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.November 12 at 1:00 AM | Behind the Markets (Ad)ADARx Pharmaceuticals to Present at the UBS Global Biopharma ConferenceNovember 9 at 8:00 AM | globenewswire.comADARx Pharmaceuticals (ADRX): Can Its SiRNA Pipeline Unlock Multiple Growth Opportunities?October 23, 2026 | rttnews.comJPMorgan Initiates ADARx Pharmaceuticals at Overweight With $38 Price TargetOctober 20, 2026 | marketscreener.comMSee More ADARx Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ADARx Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ADARx Pharmaceuticals and other key companies, straight to your email. Email Address About ADARx PharmaceuticalsADARx Pharmaceuticals (NASDAQ:ADRX) is a clinical-stage biopharmaceutical company developing RNA-targeted medicines for serious diseases. Its research focuses on oligonucleotide therapeutics designed to alter the activity of specific RNA molecules and, in turn, address disease-related gene expression. The company’s pipeline includes investigational candidates for conditions such as hereditary angioedema and complement-mediated diseases. These therapies remain in development and have not been established as approved treatments. ADARx is based in San Diego, California, and was founded to develop medicines using its RNA-targeting technology. The company’s work spans drug discovery and clinical development; details about its programs and leadership may change as its research advances.View ADARx Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping3 Pharmaceutical Stocks That Offer Safety and GrowthKeeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCoreWeave's Backlog Is Surging—Can the Stock Follow?Can Constellation Energy's Contracts Power a Stock Rebound? Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
